CAR Clinical Trials

7,834 recruitingLast updated: June 17, 2026

There are 7,834 actively recruiting car clinical trials across 121 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


CAR Trials at a Glance

7,834 actively recruiting trials for car are listed on ClinicalTrialsFinder across 6 cities in 121 countries. The largest study group is Not Applicable with 2,308 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running car studies include Mayo Clinic, National Cancer Institute (NCI), and Sun Yat-sen University.

Treatments under study

About CAR Clinical Trials

Looking for clinical trials for CAR? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new CAR trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about CAR clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 7,834 trials

Recruiting
Phase 3

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

Small Cell Lung Carcinoma
AstraZeneca70 enrolled15 locationsNCT06992609
Recruiting
Phase 1

Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

Adrenocortical Carcinoma (ACC)Carcinoma, AdrenocorticalCarcinoma, Adrenal Cortical+2 more
National Cancer Institute (NCI)32 enrolled1 locationNCT06487481
Recruiting
Phase 2

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Locally Advanced Rectal AdenocarcinomaMicrosatellite Stable Rectal Carcinoma
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT06843434
Recruiting
Phase 1

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Phase 2

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Lung Non-Small Cell Carcinoma
Alliance for Clinical Trials in Oncology164 enrolled28 locationsNCT07293247
Recruiting
Phase 3

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled293 locationsNCT06764875
Recruiting
Not Applicable

Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)

Ventricular Tachycardia (VT)
Medtronic Cardiac Ablation Solutions60 enrolled6 locationsNCT06703489
Recruiting
Phase 2

Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors

Estrogen Receptor-Positive Breast Carcinoma
Mayo Clinic80 enrolled23 locationsNCT06028022
Recruiting
Phase 3

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Stage IVB Prostate Cancer AJCC v8Metastatic Prostate AdenocarcinomaMetastatic Castration-Resistant Prostate Carcinoma
Alliance for Clinical Trials in Oncology1,524 enrolled98 locationsNCT07200830
Recruiting
Phase 2Phase 3

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal AdenocarcinomaPDAC
AbbVie900 enrolled11 locationsNCT07490301
Recruiting
Phase 2

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

Breast Carcinoma
Mayo Clinic60 enrolled5 locationsNCT05557877
Recruiting
Not Applicable

Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients

Skin CancerSquamous Cell CarcinomaBrachytherapy+3 more
Alpha Tau Medical LTD.28 enrolled11 locationsNCT06615635
Recruiting
Phase 1

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Ovarian CancerOvarian CarcinomaPlatinum Resistant Ovarian Cancer+4 more
Dana-Farber Cancer Institute18 enrolled2 locationsNCT06321484
Recruiting
Not Applicable

Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)

Pancreatic CancerMetastatic Pancreatic CancerPancreatic Adenocarcinoma+1 more
Alpha Tau Medical LTD.15 enrolled2 locationsNCT05657743
Recruiting
Not Applicable

Simulation Trial of Telemedical Support for Paramedics

Acute Respiratory FailureEmergenciesCardiopulmonary Arrest+1 more
Boston Medical Center420 enrolled9 locationsNCT06441760
Recruiting
Not Applicable

Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

Pancreatic CancerMetastatic Pancreatic CancerPancreatic Adenocarcinoma
Alpha Tau Medical LTD.40 enrolled15 locationsNCT06698458
Recruiting
Phase 1Phase 2

Study for AZD4360 in Participants With Advanced Solid Tumours

Gastric CancerGastroesophageal-junction CancerBiliary Tract Cancer+1 more
AstraZeneca117 enrolled18 locationsNCT06921928
Recruiting
Phase 1Phase 2

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 1Phase 2

Safety of HRX215 in Patients After Minor and Major Liver Resection

Liver ResectionColorectal Carcinoma Liver Metastases
HepaRegeniX GmbH80 enrolled6 locationsNCT06638502
Recruiting
Not Applicable

Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer

Pancreatic CancerPancreatic AdenocarcinomaUnresectable Pancreatic Cancer
Alpha Tau Medical LTD.15 enrolled1 locationNCT06026943